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Abstract
The easily identifiable, ubiquitous demyelination and neuronal damage that occurs within the cerebral white
matter of patients with multiple sclerosis (MS) has been the subject of extensive study. Accordingly, MS has
historically been described as a disease of the white matter. Recently, the cerebral cortex (gray matter) of patients
with MS has been recognized as an additional and major site of disease pathogenesis. This acknowledgement of
cortical tissue damage is due, in part, to more powerful MRI that allows detection of such injury and to focused
neuropathology-based investigations. Cortical tissue damage has been associated with inflammation that is less
pronounced to that which is associated with damage in the white matter. There is, however, emerging evidence
that suggests cortical damage can be closely associated with robust inflammation not only in the parenchyma, but
also in the neighboring meninges. This manuscript will highlight the current knowledge of inflammation associated
with cortical tissue injury. Historical literature along with contemporary work that focuses on both the absence and
presence of inflammation in the cerebral cortex and in the cerebral meninges will be reviewed.
Review
Introduction
Multiple sclerosis (MS) is widely viewed as a disease of
white matter [1]. White matter lesions that include
demyelination and neuronal damage are readily visible
by MRI and macroscopically upon autopsy [2,3]. White
matter lesions visualized via MRI are used to diagnose
MS, in effect making these lesions the leading pathogno-
monic sign for MS [4]. The most widely accepted ani-
mal model, experimental autoimmune encephalomyelitis
(EAE) in rodents, is based on an induced autoimmune
reaction against myelin proteins of white matter of the
central nervous system (CNS) [5]. That such injury is
easily identifiable and ubiquitous, white matter pathol-
ogy has been the subject of considerable attention.
Although white matter damage is clearly present in the
disease, it is not the only site within the CNS where the
pathology of MS occurs. The cerebral cortex of the MS
brain has recently been recognized as a major site of
disease pathogenesis, perhaps now moving toward equal
importance as the white matter. This is not to say that
tissue damage in the cortex was never recognized. Gray
matter damage has been described in MS since the ear-
liest known reference to the disease phenotype. In
Pathological Anatomy (1838), the Scottish pathologist
Robert Carswell describes and illustrates a spinal cord
that is viewed, by medical historians, to be among the
very first documented cases of MS [6,7]. In this report
Carswell notes the presence of lesions and atrophy.
Regarding the grey matter damage, he writes, “The
depth to which the medullary substance was affected in
this matter varied from half a line to three or four lines,
and on dividing the cord, it was seen to penetrate as far
as the gray substance.” His illustrations of the spinal
cord’s traverse sections demonstrate lesions exclusive to
the white matter and those that have extended from the
white into the gray matter. Although MS was not
named a separate disease until 30 years later in Jean-
Martin Charcot’s Histology de la Sclerose en Plaque
(1868), in 1838 Carswell recognized that the currently
unclassified CNS pathology, which he described, was
not restricted to the white matter. In this review, we
summarize the present-day knowledge of the role that
the immune system plays in MS cortical tissue damage,
focusing on the cellular and molecular characteristics of
the immune infiltrate found within the cortex and
meninges.
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Characteristics of cortical lesions
Despite acknowledgement in the early studies of MS
and that the disease includes cognitive symptoms, corti-
cal involvement in MS has been given less attention
than the characteristic white matter lesions until
recently. Given that cortical damage is now recognized
as a major site of disease pathology, why has this
occurred? The most plausible explanation is that cortical
lesions are simply not obvious by the standard means of
visualization (MRI and histopathology) and early macro-
scopic studies suggested that they represent a minor
fraction of damage that occurs in the brain [8]. Cortical
immune infiltrates associated with tissue damage are
often sparse [9]. In the absence of an immune infiltrate,
these lesions maintain a normal water concentration
and therefore are not hyperintense on T2 weighted MRI
like white matter lesions [10] highlighting why they are
not easily visualized. Although identification of indivi-
dual cortical lesions in MS are elusive, cortical atrophy
in patients with MS is apparent, particularly in the hip-
pocampus [11]. It has been established that the cortex
atrophies more rapidly than white matter in patients
with MS and that the degree of cortical atrophy is inde-
pendent of that which occurs in the white matter [12].
Cortical atrophy correlates with the clinical progression
of the disease better than the white matter lesion load
[13-15]. These findings support the idea that cortical
damage may better explain the symptoms of cognitive
impairment associated with MS, such as anterograde
memory loss, whereas white matter lesions manifest
clinically as motor deficits [11]. There is not an appreci-
able correlation [16,17] between white matter lesion
load and cortical tissue damage, as measured by imaging
and histochemistry, indicating that the pathological pro-
cesses may, to some extent, occur independently. Corti-
cal lesions have been classified using a number of
systems [18-20]. All of the systems share similar descrip-
tions of the three major lesion types [21]. These are
identified as type I (contiguous with subcortical white
matter lesions), type II (exclusively intracortical and
extending through all the cortical layers), and type III
(extended from the pial surface to the superficial cortical
layers). White matter lesions in chronic MS are often
characterized by severe BBB breakdown and often
include a lymphocytic infiltrate. Interestingly, cortical
lesions from the same subject lack detectable plasma/
serum-derived proteins and basement membrane altera-
tions indicating that the BBB disruption is not always
associated with intracortical demyelination in progres-
sive MS [22].
The examination of inflammation in MS brain tissue
principally includes marking for T cells, B cells, den-
dritic cells, microglia and macrophages. T cell subsets
such as T helpers (CD4+), cytotoxic (CD8+), and
memory T cells, which play different roles, are also of
interest. B cells are examined less often and plasma
cells are often not included in such analyses. It is use-
ful, however, to include markers for plasma cells that
may secrete pathogenic autoantibody. Identifying B
cells is important as they may function as very effective
antigen presenting cells (APC) in MS and their abla-
tion results in decreased lesion load [23]. Application
of such immunohistochemistry to cortical tissue has
highlighted a further contrast with most white matter
lesions. That is, cortical lesions in progressive MS har-
bor considerably less inflammation than that which is
observed in the white matter. It is important to point
out that the absence of ongoing active cortical demye-
lination is often accompanied by a paucity of infiltrat-
ing immune cells. Active cortical demyelination can be
identified by the presence of recent myelin degradation
products in macrophages/microglia. When such active
lesions are examined, more inflammation is observed,
but this inflammation is much less pronounced than
that in the white matter. Sparse infiltrates associated
with inactive demyelination does not usually differ
with control areas in MS brain that are not damaged
[17,20,24]. It should be pointed out that regions of MS
brain that are free of injury often harbor immune cells.
Activated effector memory T cells (TEM), B cells and T
cells reside in the white matter and cortical tissue that
appears to be free of lesions [25-27]. The cortical
lesions that include few detectable infiltrates, sharply
contrast those of the white matter lesions from the
same brain that have conspicuous infiltrates [28] indi-
cating, perhaps, that the location of a lesion may influ-
ence the immune response. The little inflammation
that is present is variable depending on the type of
cortical lesion. Lesions that extend through the white
matter and cortex (type I) and deep cortical lesions
have higher counts of inflammatory cells than those
that are exclusively intracortical [29,30], but both have
significantly less inflammation than those of white
matter from the same brain [31]. The minor infiltrate
in the cortical lesions include activated microglia,
scarce myelin-laden macrophages, CD3+ T cells, CD20
+ B cells, and rare CD138+ plasma cells. Interestingly,
microarray-based gene expression profiling has
revealed that immunoglobulin-related genes are upre-
gulated in the cortex of progressive MS specimens
[32]. These data appear to stand in contrast to the
immunohistochemistry-based studies that suggest
inflammation is not a characteristic of cortical tissue
damage. Further examination of the same specimens
used in the microarray work showed that both plasma
cells, which robustly express immunoglobulin, and
some B cells present in the meninges were likely con-
tributing to the variation in expression.
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Cortical injury associated with inflammation
To date, a modest amount of data has been presented to
support a role for inflammation in cortical tissue
damage. However, a picture contesting the view that
cortical demyelination occurs in the absence of inflam-
mation is beginning to emerge. Indeed, a recent study
using biopsy material derived from early MS (diagnosis
confirmed through follow up) clearly demonstrates that
demyelination of pure cortical tissue includes plainly
evident inflammation [33]. Here, infiltrating macro-
phages associated with cortical tissue damage contained
products of degraded myelin such as PLP and CNPase.
Lymphocytes were present in both the exclusively par-
enchymal and the perivascular regions. This infiltrate
included T cells, B cells and antibody-producing plasma
cells. The CD4+ T cell population (determined by esti-
mating the number of CD3+ cells not stained with
CD8), were less abundant than CD8+ T cells. In addi-
tion to demyelination, neuronal and axonal damage was
also recorded. Interestingly, evidence for white matter
demyelination via MRI was not observed at this early
stage of the disease, suggesting that cortical tissue
damage may precede tissue injury in the white matter.
That more progressive and/or chronic forms of MS can
include cortical damage that may not be associated with
inflammation, raises questions regarding the possibility
that resolution of cortical inflammation in some stages
of MS may occur. A growing number of models of MS
include intracortical lesions with extensive demyelina-
tion associated with inflammation [34-36]. In one such
recently described rodent model [37], the cortical
inflammatory infiltrate was shown to considerably
diminish shortly after establishment of the tissue
damage suggesting that a similar course of resolution
may occur in some stages of the human disease.
So, it seems that early MS may include cortical
damage associated with considerable inflammation while
progressive stages harbor less cortical inflammation.
Why have these vast differences in MS cortical inflam-
mation only come to light recently? It is important to
bear in mind that much of the research that requires
MS CNS tissue shares a common denominator, that is
many studies are largely focused on progressive disease.
Such bias is often unavoidable in MS research because
the majority of clinical specimens available for research
are collected nearly invariably from autopsy with more
rare collections derived from biopsy. This, of course,
results in an unavoidable, but evident sampling bias.
Furthermore, the majority of autopsy specimens are
derived from progressive late-stage disease and biopsies
are often derived from the early stages of disease, which
present a very different pathological course. Thus, much
of the disease spectrum is not well represented. Larger
studies, with specimens derived from multiple centers
are needed to more precisely understand the relation-
ship between cortical and white matter inflammation at
different stages of the disease.
Cortical demyelination and inflammation: meningeal
lymphocytes
Follicles of the lymph nodes contain germinal centers
populated by antigen-activated B cells. Within this
structure, B cells undergo antigen-driven clonal expan-
sion, affinity maturation and differentiation into memory
B cells and plasma cells. Among the support structure
required for this to occur are T cells and follicular den-
dritic cells (FDC). FDCs present antigen and provide
survival and proliferation signals to B cells. These cells
also produce a B cell chemoattractant, CXCL13, which
regulates migration of B cells. FDC can be recognized
by their expression of CD35. In several autoimmune dis-
eases, such as rheumatoid arthritis (RA) [38], substantial
lymphocyte infiltrations are seen at the site of autoim-
mune-mediated tissue damage. These infiltrates, which
are not associated with lymphoid tissue, often form
germinal center (GC) -like structures [39] where the
presence of FDCs as well as T and B cells have been
demonstrated. In addition to RA, such ectopic GCs or
ectopic lymphoid aggregates are observed in the tissue
of patients with RA, Sjogren’s syndrome, Crohn’s disease
and Hashimoto’s thyroditis [40-42] and within some
tumors [43-46]. These structures are thought to be a
source of the autoreactive B cells and antibodies and
participate in the maintenance of the autoimmune
response, although more investigation is needed to con-
firm this.
Meningeal inflammation in the MS CNS, which has
been the subject of much investigation in the last dec-
ade, was described in the early twentieth century [47].
Additional early studies of MS tissue report that inflam-
matory changes affected not only the leptomeninges and
arachnoid, but also dura mater. The inflammation
described in these reports was either acute or chronic
and often led to thickening and fusion of the leptome-
ninges with the dura [48,49]. The presence of meningeal
inflammation in some animal models of MS has also
been described [50,51]. Among the more contemporary
reports that describe inflammation in the MS CNS that
appeared to adopt an organized morphology, is that of
Prineas [52]. Here, white matter-associated perivascular
spaces holding lymphocyte containing capillaries and
plasma cells resemble lymph node architecture. In addi-
tion, Guseo and Jellinger in 1975 described the infil-
trates that they found to populate the meninges and
deep sulci of MS brain as “grouped” [53]. These orga-
nized structures present in the meninges of the MS
CNS have been more clearly defined in the last decade
[54]. They resemble the B cell follicles observed in
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autoimmune tissue and neoplasms and appear to be
exclusive to the meninges, as they are not found at the
site of parenchymal lesions. Meningeal infiltrates in MS
differ from those found in perivascular regions of the
parenchyma; the network of follicular dendritic cells is
not present in the parenchyma, clusters of proliferating
B cells appear exclusively in the meninges, as does the
expression of lymphocyte homing chemokines. They are
not exclusive to MS [55], but do seem rare in cases of
inflammatory CNS disease. Larger studies are needed to
more clearly define their distribution.
B-cells, T-cells, plasma cells, and a supporting network
of follicular dendritic cells that imitate those in second-
ary lymph nodes populate these follicles. These lympho-
cytes are often associated with meningeal blood vessels.
Meningeal follicles emulate peripheral lymphoid germ-
inal centers in that proliferating B cells, evidenced by
Ki67 expression, collect within the structure and lym-
phocyte homing chemokines such as the chemoattrac-
tant CXCL13 expressed by CD35 positive FDCs have
been observed in a subset of patients [54]. These folli-
cles, however, are incomplete when compared to those
found in secondary lymphoid organs. They do not own
all of the characteristic structures, such as HEVs, or all
of the homing chemokines, such as CCL21 or PNad.
Meningeal B cell follicles were evident in about half of
secondary progressive MS cases examined in one study
[56] but rare or absent in primary progressive cases
reported in another study by the same team [55].
Another study reported that these meningeal structures
are present in both primary and secondary progressive
disease [9] and that an active disease process correlated
with their presence. Many progressive cases can include
a modest meningeal immune cell infiltrate that do not
include B cell follicle structures (lack organization) [55].
Thus in general terms, there appears to be a gradient of
meningeal inflammation that ranges from absent to
moderate and diffuse and then to that which includes
the formation of follicle-like aggregates. This gradient is
also reflected in the severity of active demyelination and
tissue damage. Of course, whether tissue without or
with moderate inflammation had previously harbored
follicles that have resolved is not known. Larger, and
certainly more complex studies will be required to
determine if such follicles appear in relapsing remitting
MS before the transition to late-stage or progressive dis-
ease has occurred. Imaging techniques are likely to be
required for longitudinal studies that are not possible
with autopsy-derived specimens.
Analysis of whole bi-hemispheric sections clearly illus-
trates that the B cell follicle-like structures are numer-
ous and found widely distributed throughout meninges
and most often reside in the deep infoldings of the cere-
bral sulci [57]. They do however vary considerably in
number of cells per structure and in structures per case.
Specimens harboring follicles often include B cell and
plasma cell infiltrates in white matter lesions, whereas
those without follicles typically have fewer white matter
associated B cell infiltrates. There appear to be regions
of meningeal inflammation, which are not associated
with tissue damage [58], but there are many instances
where the two are closely linked. Increased cortical
lesion load, in terms of quantity and extent of demyeli-
nation, correlates with the presence of meningeal folli-
cles, as does the preponderance of subpial (type III)
lesions (extended from the pial surface to the superficial
cortical layers). Follicles are most often found adjacent
to these subpial lesions. These collective data, of course,
suggest that the formation of follicles is related to or
plays a role in damage of the cortical tissue. The pre-
sence of follicles also correlates with increases in cortical
atrophy and loss of neurons, astrocytes, and oligoden-
drocytes [55]. The tissue damage occurs in a gradient
that begins at the pial surface then decreases with dis-
tance from this region. Cytotoxic factors diffusing from
the meningeal compartment are suspected to play a role
in this damage. The degree of disease course severity
also appears to correlate with the presence of organized
meningeal inflammation, whether such formation is
contributory or a consequence of the severity remains
to be determined.
It is clear from these data that a compartmentalized B
cell response occurs within the MS CNS. Many stages
of B cell differentiation that are usually observed only in
secondary lymphoid organs appear to occur, suggesting
a favorable microenvironment is arranged in the CNS.
This proliferation of B cells in the MS CNS has been
attributed to EBV infection [59,60], but this has been
considerably controversial because a number of groups
have found that EBV+ B cells are not overrepresented in
the MS CNS [32,61-63]. Thus, the question remains as
to whether peripherally activated B cells are selectively
recruited to the CNS tissue or if B cells are recruited
and then mature locally and differentiate into plasma
cells emulating a germinal center. Interestingly, a por-
tion of B cells that populate white matter parenchymal
lesions are clonally related to those in meninges, and
both of these populations have clonal siblings repre-
sented in the CSF [27]. And the CSF IgG that comprises
the characteristic oligoclonal bands are derived from
this network of CNS resident B cells [64,65]. It remains
to be understood how this network is established in
terms of its origin. That cervical lymph nodes harbor
brain-derived antigens [66] suggests that cells that com-
prise this network can be associated with the periphery.
However, such antigens appear only after tissue damage
has occurred hence it remains possible that these cells
first experience antigen in the CNS.
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Cortical inflammation in models of MS
A thorough review of models that emulate MS cortical
pathology is beyond the scope of this review, however
there are studies that highlight the findings in the
human disease and guide questions for future study. For
example, it is interesting to note that MS models emu-
lating cortical tissue damage not only harbor immune
infiltrates of T cells, B cells and macrophages, but also
appear to depend on antibodies and complement. A rat
model of MS displayed extensive cortical demyelination
associated with deposition of immunoglobulin on myelin
sheaths [35]. Similarly, a non-human-primate model for
MS [34] revealed immunoglobulin and complement c9
deposition in regions of cortical demyelination. Derfuss
et al. developed a mouse model for gray matter damage
in MS in which immune damage mediated by TAG-1
(contactin-2 homologue)-specific T cells resulted in gray
matter inflammation in the spinal cord and cortex.
When the TAG-1 specific T cells were co-transferred
with a monoclonal antibody against myelin oligodendro-
cyte glycoprotein (MOG), focal perivascular demyelina-
tion occurred in the cortex. They also found contactin-2
specific T cells and antibodies in MS patients, suggest-
ing that an autoimmune response against the protein
may be related to MS gray matter pathology [67]. Simi-
larly, Huizinga et al. produced an MS mouse model that
exhibits axonal loss and cortical lesions by inducing
autoimmunity against neurofilament light (NF-1). These
models, along with the rat and primate models, support
the idea that direct immunological damage to the corti-
cal tissue plays a role in the observed pathology [68].
There is also evidence that more indirect immune-
mediated damage to gray matter contribute to the
pathology of MS. Centonze and colleagues suggest that
cortical damage could be caused, in part, by collateral
damage of pro-inflammatory cytokines released by
immune mediators reacting to myelin proteins. Here,
cytokines, such as IL-1b, TNFa, and INFg, released by T
cells and microglia increase AMPA receptor activity on
neurons, contributing to neuronal damage and cortical
pathology in models of MS [69].
Conclusions
Future work is necessary to more clearly define the
emerging picture of immune-associated cortical demyeli-
nation that occurs in MS. Understanding the relation-
ship between the profound inflammation commonly
seen in the white matter and that of the cortex, which
seems to be less consistently observed, is certainly a
priority. Many other questions remain: From where do
the meningeal infiltrates arise? Do the cells that popu-
late these structures emerge from the periphery then
migrate to this compartment or do pioneer naïve cells
experience antigen in the CNS then proliferate
exclusively within this compartment? How exactly do
they affect tissue damage? Are these cells autoreactive?
The antigen(s), whether they are self, environmental or
unique to individuals, unquestionably need to be
defined. While important recent findings have strength-
ened our understanding of MS cortical tissue damage
they also highlight the critical need to further under-
stand cortical pathology and pathogenesis.
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